Disclosed herein are methods of delivering an agent to a subject. Further disclosed herein are methods of treating a disease or disorder in a subject. The methods may include administering to the subject a chondroitinase polypeptide or a polynucleotide encoding a chondroitinase polypeptide in an amount sufficient to degrade glycosaminoglycans, and administering to the subject the agent. The methods may further include administering a hyaluronidase polypeptide or a polynucleotide encoding a hyaluronidase.

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

Disclosed herein are combinations of inhibitors of B cell maturation and recombinant nucleic acid molecules encoding synthethic antibodies, and their use for extending the duration of circulating synthetic antibodies and for treating diseases and disorders.

In vitro method for detection of infections caused by Pseudomonas aeruginosa. The present invention relates to compounds of general Formula (I) and to their use as haptens. Moreover, the present invention also refers to conjugates comprising the haptens of the invention and to their use for obtaining antibodies. Finally, the invention also relates to an in vitro method for the detection of infections caused by Pseudomonas aeruginosa by means of the identification and/or quantification of the main signaling molecules from the pqs quorum sensing system.

##STR00001##

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

The invention relates to a monoclonal antibody against the OprF protein of Pseudomonas aeruginosa or to a functional fragment of this antibody. This antibody or antibody fragment is particularly useful for the preventive or curative treatment of infections with Pseudomonas aeruginosa.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

A method for preventing or treating nosocomial diseases, e.g., diseases caused by Pseudomonas aeruginosa, is provided. The method includes administering to a susceptible human a specified dose of a bispecific antibody that that specifically binds Pseudomonas aeruginosa Psl and PcrV.

Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived IgM and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products.

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind to Pseudomonas PcrV as well as vectors and host cells comprising the same.